Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Background: We evaluated the effects of low doses of the tyrosine kinase Abelson (Abl) inhibitor Nilotinib, on safety and pharmacokinetics in Parkinson’s disease dementia or dementia with Lewy bodies. Objectives: The primary outcomes of this study were safety and tolerability; pharmacokinetics and target engagement were secondary, while clinical outcomes were exploratory. Methods: Twelve subjects were randomized into 150 mg ( n = 5) or 300 mg ( n = 7) groups and received Nilotinib orally every day for 24 weeks. Results: This study shows that 150 mg and 300 mg doses of Nilotinib appear to be safe and tolerated in subjects with advanced Parkinson’s disease. Nilotinib is detectable in the cerebrospinal fluid (CSF) and seems to engage the target Abl. Motor and cognitive outcomes suggest a possible beneficial effect on clinical outcomes. The CSF levels of homovanillic acid are significantly increased between baseline and 24 weeks of treatment. Exploratory CSF biomarkers were measured. Conclusions: This small proof-of-concept study lacks a placebo group and participants were not homogenous, resulting in baseline differences between and within groups. This limits the interpretations of the biomarker and clinical data, and any conclusions should be drawn cautiously. Nonetheless, the collective observations suggest that it is warranted to evaluate the safety and efficacy of Nilotinib in larger randomized, double-blind, placebo-controlled trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Nilotinib, proven to improve mitochondrial function,517 and clinical trials have been initiated to explore its application in PD.518,519”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [519]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ubiquitination Increases Parkin Activity to Promote Autophagic α-Synuclein Clearance
Lonskaya, I., Desforges, N. M., Hebron, M. L., & Moussa, C. E.-H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083914 · Cited by 86
Self-citationRetractedRepertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Cui, C., Cui, J., Jin, F., Cui, Y., Li, R., Jiang, X., Tian, Y., Wang, K., Jiang, P., & Gao, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479571 · Cited by 5,203
The role of autophagy in neurodegenerative disease
Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059
Extensive Involvement of Autophagy in Alzheimer Disease: An Immuno-Electron Microscopy Study
Nixon, R. A., Wegiel, J., Kumar, A., Yu, W. H., Peterhoff, C., Cataldo, A., & Cuervo, A. M. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.113 · Cited by 1,588
α-Synuclein Is Degraded by Both Autophagy and the Proteasome
Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., & Rubinsztein, D. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300227200 · Cited by 1,429
mTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
Boland, B., Kumar, A., Lee, S., Platt, F. M., Wegiel, J., Yu, W. H., & Nixon, R. A. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0800-08.2008 · Cited by 1,119
Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy
Ravikumar, B. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.9.1107 · Cited by 1,111
DJ‐1 has a role in antioxidative stress to prevent cell death
Taira, T., Saito, Y., Niki, T., Iguchi‐Ariga, S. M. M., Takahashi, K., & Ariga, H. (2004) · EMBO reports · doi:10.1038/sj.embor.7400074 · Cited by 853
Research works printed but not linked: 2
- 10.1007/s00109-013-1112-3 · DOI · Paper page
- Kang JH, 2013, JAMA Neurol, 70, 1277
Cited by
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870
Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing
Boland, B., Yu, W. H., Corti, O., Mollereau, B., Henriques, A., Bezard, E., Pastores, G. M., Rubinsztein, D. C., Nixon, R. A., Duchen, M. R., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.109 · Cited by 558
Progress towards therapies for disease modification in Parkinson's disease
Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R., & Foltynie, T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00061-2 · Cited by 419
Lang, A. E., & Espay, A. J. (2018) · Movement Disorders · doi:10.1002/mds.27360 · Cited by 370
Old Drugs as New Treatments for Neurodegenerative Diseases
Durães, F., Pinto, M., & Sousa, E. (2018) · Pharmaceuticals · doi:10.3390/ph11020044 · Cited by 343
Emerging therapies in Parkinson disease — repurposed drugs and new approaches
Elkouzi, A., Vedam-Mai, V., Eisinger, R. S., & Okun, M. S. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0155-7 · Cited by 300
Therapeutic approaches to target alpha-synuclein pathology
Brundin, P., Dave, K. D., & Kordower, J. H. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.003 · Cited by 242
Tau Protein Interaction Partners and Their Roles in Alzheimer’s Disease and Other Tauopathies
Sinsky, J., Pichlerova, K., & Hanes, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179207 · Cited by 220
“Nilotinib Ab1 kinase inhibitor Phase II (AD/PD) Unknown NCT02947893 [606]”
BackgroundRecent progress of drug nanoformulations targeting to brain
Khan, A. R., Yang, X., Fu, M., & Zhai, G. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.004 · Cited by 213
New Avenues for the Treatment of Huntington’s Disease
Kim, A., Lalonde, K., Truesdell, A., Gomes Welter, P., Brocardo, P. S., Rosenstock, T. R., & Gil-Mohapel, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168363 · Cited by 191
Pagan, F. L., Hebron, M. L., Wilmarth, B., Torres-Yaghi, Y., Lawler, A., Mundel, E. E., Yusuf, N., Starr, N. J., Anjum, M., Arellano, J., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.4200 · Cited by 185
Self-citationPharmacological Treatment of Parkinson’s Disease
Zahoor, I., Shafi, A., & Haq, E. (2018) · Codon Publications eBooks · doi:10.15586/codonpublications.parkinsonsdisease.2018.ch7 · Cited by 184
Magalhães, P., & Lashuel, H. A. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00357-0 · Cited by 184
Current approaches to the treatment of Parkinson’s Disease
Ellis, J. M., & Fell, M. J. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.07.075 · Cited by 183
Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic
Sardi, S. P., Cedarbaum, J. M., & Brundin, P. (2018) · Movement Disorders · doi:10.1002/mds.27414 · Cited by 170
Zhang, K., Zhu, S., Li, J., Jiang, T., Feng, L., Pei, J., Wang, G., Ouyang, L., & Liu, B. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.016 · Cited by 169
Recent developments in the treatment of Parkinson's Disease
Stoker, T. B., & Barker, R. A. (2020) · F1000Research · doi:10.12688/f1000research.25634.1 · Cited by 166
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
Simuni, T., Fiske, B., Merchant, K., Coffey, C. S., Klingner, E., Caspell-Garcia, C., Lafontant, D.-E., Matthews, H., Wyse, R. K., Brundin, P., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.4725 · Cited by 149
Emerging Treatment Approaches for Parkinson’s Disease
Stoker, T. B., Torsney, K., & Barker, R. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00693 · Cited by 148
Current and Possible Future Therapeutic Options for Huntington’s Disease
Ferguson, M. W., Kennedy, C. J., Palpagama, T. H., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2022) · Journal of Central Nervous System Disease · doi:10.1177/11795735221092517 · Cited by 147
Recent advances in treating Parkinson’s disease
Oertel, W. H. (2017) · F1000Research · doi:10.12688/f1000research.10100.1 · Cited by 123
Pillaiyar, T., Meenakshisundaram, S., Manickam, M., & Sankaranarayanan, M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112275 · Cited by 140
Simchovitz, A., Hanan, M., Niederhoffer, N., Madrer, N., Yayon, N., Bennett, E. R., Greenberg, D. S., Kadener, S., & Soreq, H. (2019) · The FASEB Journal · doi:10.1096/fj.201900830r · Cited by 119
Recent Advances in Drug Therapy for Parkinson's Disease
Murakami, H., Shiraishi, T., Umehara, T., Omoto, S., & Iguchi, Y. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8940-21 · Cited by 133
α-Synuclein in Parkinson’s disease: causal or bystander?
Riederer, P. F., Berg, D., Casadei, N., Cheng, F., Claßen, J., Dresel, C., Jost, W. H., Krüger, R., Müller, T., Reichmann, H., et al. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02025-9 · Cited by 128
Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer’s Disease
Turner, R. S., Hebron, M. L., Lawler, A., Mundel, E. E., Yusuf, N., Starr, J. N., Anjum, M., Pagan, F., Torres‐Yaghi, Y., Shi, W., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25775 · Cited by 126
Self-citationThe Vicious Cycle Between α ‐Synuclein Aggregation and Autophagic‐Lysosomal Dysfunction
Bellomo, G., Paciotti, S., Gatticchi, L., & Parnetti, L. (2019) · Movement Disorders · doi:10.1002/mds.27895 · Cited by 127
Pagan, F. L., Hebron, M. L., Wilmarth, B., Torres‐Yaghi, Y., Lawler, A., Mundel, E. E., Yusuf, N., Starr, N. J., Arellano, J., Howard, H. H., et al. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.470 · Cited by 118
Self-citationPromising drug targets and associated therapeutic interventions in Parkinson’s disease
Singh, M., Singh, B., Rai, S., Singh, P., Varshney, R., Chaturvedi, V., & Vamanu, E. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.306066 · Cited by 108
Treatment of Parkinson’s Disease with Cognitive Impairment: Current Approaches and Future Directions
Sun, C. E., & Armstrong, M. J. (2021) · Behavioral Sciences · doi:10.3390/bs11040054 · Cited by 114
The Journey of DDR1 and DDR2 Kinase Inhibitors as Rising Stars in the Fight Against Cancer
Elkamhawy, A., Lu, Q., Nada, H., Woo, J., Quan, G., & Lee, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126535 · Cited by 114
c-Abl and Parkinson’s Disease: Mechanisms and Therapeutic Potential
Brahmachari, S., Karuppagounder, S. S., Ge, P., Lee, S., Dawson, V. L., Dawson, T. M., & Ko, H. S. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-171191 · Cited by 99
Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease
Jasutkar, H. G., Oh, S. E., & Mouradian, M. M. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000133 · Cited by 110
Biological and Clinical Implications of Comorbidities in Parkinson’s Disease
Santiago, J. A., Bottero, V., & Potashkin, J. A. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00394 · Cited by 95
Savitt, D., & Jankovic, J. J. (2019) · Drugs · doi:10.1007/s40265-019-01104-1 · Cited by 101
Expanding the role of proteasome homeostasis in Parkinson’s disease: beyond protein breakdown
Bi, M., Du, X., Jiao, Q., Chen, X., & Jiang, H. F. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03441-0 · Cited by 99
La Barbera, L., Vedele, F., Nobili, A., Krashia, P., Spoleti, E., Latagliata, E. C., Cutuli, D., Cauzzi, E., Marino, R., Viscomi, M. T., et al. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102031 · Cited by 98
Autophagy in Synucleinopathy: The Overwhelmed and Defective Machinery
Arotçarena, M.-L., Teil, M., & Dehay, B. (2019) · Cells · doi:10.3390/cells8060565 · Cited by 97
Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers
Barba, L., Paoletti, F. P., Bellomo, G., Gaetani, L., Halbgebauer, S., Oeckl, P., Otto, M., & Parnetti, L. (2022) · Movement Disorders · doi:10.1002/mds.28941 · Cited by 92
Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies
Silva, M. C., & Haggarty, S. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238948 · Cited by 85
Targeting tau: clinical trials and novel therapeutic approaches
VandeVrede, L., Boxer, A. L., & Polydoro, M. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.134919 · Cited by 90
Enhancing autophagy in Alzheimer's disease through drug repositioning
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89
Lee, S., Kim, S., Park, Y. J., Yun, S. P., Kwon, S., Kim, D., Kim, D.-Y., Shin, J. S., Cho, D. J., Lee, G. Y., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy143 · Cited by 88
Targeting α-Synuclein for PD Therapeutics: A Pursuit on All Fronts
Teil, M., Arotçarena, M.-L., Faggiani, E., Laferrière, F., Bézard, E., & Dehay, B. (2020) · Biomolecules · doi:10.3390/biom10030391 · Cited by 85
MicroRNA-7 facilitates the degradation of alpha-synuclein and its aggregates by promoting autophagy
Choi, D. C., Yoo, M., Kabaria, S., & Junn, E. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.05.009 · Cited by 81
Tian, X., Zhang, H., Heimbach, T., He, H., Buchbinder, A., Aghoghovbia, M., & Hourcade‐Potelleret, F. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1312 · Cited by 80
Pharmacotherapy of Alzheimer’s Disease: Seeking Clarity in a Time of Uncertainty
Husna Ibrahim, N., Yahaya, M. F., Mohamed, W., Teoh, S. L., Hui, C. K., & Kumar, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00261 · Cited by 72
Preserving Lysosomal Function in the Aging Brain: Insights from Neurodegeneration
Peng, W., Minakaki, G., Nguyen, M., & Krainc, D. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00742-3 · Cited by 79
Lei, Q., Wu, T., Wu, J., Hu, X., Guan, Y., Wang, Y., Yan, J., & Shi, G. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12374 · Cited by 80
Mansour, H. M., Fawzy, H. M., El-Khatib, A. S., & Khattab, M. M. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.06.013 · Cited by 67
Kim, J., Lee, H.-J., Park, J.-H., Cha, B.-Y., & Hoe, H.-S. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02549-0 · Cited by 69
Vargas, L. M., Cerpa, W. F., Muñoz, F. J., Zanlungo, S., & Alvarez, A. R. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.01.023 · Cited by 75
Fowler, A. J., Hebron, M., Missner, A. A., Wang, R., Gao, X., Kurd-Misto, B. T., Liu, X., & Moussa, C. E.-H. (2019) · Drugs in R&D · doi:10.1007/s40268-019-0266-z · Cited by 68
Self-citationα-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment
Karim, M. R., Liao, E. E., Kim, J., Meints, J. P., Martínez, H., Pletniková, O., Troncoso, J. C., & Lee, M. K. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00364-w · Cited by 73
Jayaswamy, P. K., Vijaykrishnaraj, M., Patil, P., Alexander, L. M., Kellarai, A., & Shetty, P. K. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101791 · Cited by 72
The Emerging Roles of Autophagy in Human Diseases
Lei, Y., & Klionsky, D. J. (2021) · Biomedicines · doi:10.3390/biomedicines9111651 · Cited by 70
Activation mechanisms of the E3 ubiquitin ligase parkin
Panicker, N., Dawson, V. L., & Dawson, T. M. (2017) · Biochemical Journal · doi:10.1042/bcj20170476 · Cited by 65
Membrane interactions of intrinsically disordered proteins: The example of alpha-synuclein
Das, T., & Eliezer, D. (2019) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2019.05.001 · Cited by 60
Long‐Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease
Pagán, F., Wilmarth, B., Torres-Yaghi, Y. A., Hebron, M. L., Mulki, S., Ferrante, D., Matar, S., Ahn, J., & Moussa, C. (2020) · Movement Disorders · doi:10.1002/mds.28389 · Cited by 65
Self-citationThe Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson’s Disease
Polissidis, A., Petropoulou-Vathi, L., Nakos‐Bimpos, M., & Rideout, H. J. (2020) · Biomolecules · doi:10.3390/biom10060912 · Cited by 64
Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity
Werner, M. H., & Olanow, C. W. (2021) · Movement Disorders · doi:10.1002/mds.28858 · Cited by 63
Recent advancement in therapeutic strategies for Alzheimer’s disease: Insights from clinical trials
Khan, T., Waseem, R., Shahid, M., Ansari, J., Ahanger, I. A., Hassan, M. I., & Islam, A. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102113 · Cited by 62
Drug Repurposing in Parkinson’s Disease
Athauda, D. S., & Foltynie, T. (2018) · CNS Drugs · doi:10.1007/s40263-018-0548-y · Cited by 62
Lysosomal dysfunction in α-synuclein pathology: molecular mechanisms and therapeutic strategies
Dai, L., Liu, M., Ke, W., Chen, L., Fang, X., & Zhang, Z. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05419-5 · Cited by 61
Sonti, R., Hertel-Hering, I., Lamontanara, A. J., Hantschel, O. D., & Grzesiek, S. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b12430 · Cited by 60
Clinically Precedented Protein Kinases: Rationale for Their Use in Neurodegenerative Disease
Benn, C., & Dawson, L. A. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00242 · Cited by 61
Kakoti, B. B., Bezbaruah, R., & Ahmed, N. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1007315 · Cited by 59
Multi-Target-Directed Ligands as an Effective Strategy for the Treatment of Alzheimer’s Disease
Kumar, R., Kumar, V., Kumar, B., Thakur, A., & Dwivedi, A. R. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210512005508 · Cited by 57
Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders
Shah, S., Dooms, M. M., Amaral‐Garcia, S., & Igoillo‐Esteve, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.768023 · Cited by 55
New hopes for disease modification in Parkinson's Disease
Poewe, W. H., Seppi, K., Marini, K., & Mahlknecht, P. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108085 · Cited by 55
Activating Autophagy as a Therapeutic Strategy for Parkinson’s Disease
Fowler, A. J., & Moussa, C. (2018) · CNS Drugs · doi:10.1007/s40263-018-0497-5 · Cited by 54
Self-citationApproaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned
Hung, A. Y., & Schwarzschild, M. A. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00964-w · Cited by 54
c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson’s Disease
Lindholm, D., Pham, D. D., Cascone, A., Eriksson, O., Wennerberg, K., & Saarma, M. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00254 · Cited by 53
Protein clearance strategies for disease intervention
Hommen, F., Bilican, S., & Vílchez, D. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02431-y · Cited by 51
Nakmode, D. D., Day, C. M., Song, Y., & Garg, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051503 · Cited by 51
Alpha-synuclein and iron: two keys unlocking Parkinson’s disease
Lingor, P., Carboni, E., & Koch, J. C. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1695-x · Cited by 51
Molecular and Cellular Interactions in Pathogenesis of Sporadic Parkinson Disease
Долгачева, Л. П., Зинченко, В. П., & Goncharov, N. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113043 · Cited by 51
Clinical drug development for dementia with Lewy bodies: past and present
Lee, G., Cummings, J. L., Decourt, B., Leverenz, J. B., & Sabbagh, M. N. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1681398 · Cited by 48
Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases
Fowler, A. J., Hebron, M. L., Balaraman, K., Shi, W., Missner, A. A., Greenzaid, J. D., Chiu, T. L., Ullman, C. J., Weatherdon, E., Duka, V., et al. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa177 · Cited by 48
Self-citationNeuroprotective effects of memantine via enhancement of autophagy
Hirano, K., Fujimaki, M., Sasazawa, Y., Yamaguchi, A., Ishikawa, K., Miyamoto, K., Souma, S., Furuya, N., Imamichi, Y., Yamada, D., et al. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.08.025 · Cited by 47
c-Abl Inhibition Activates TFEB and Promotes Cellular Clearance in a Lysosomal Disorder
Contreras, P. S., Tapía, P., González-Hódar, L., Peluso, I., Soldati, C., Napolitano, G., Matarese, M., Heras, M. L., Valls, C., Martinez, A. N., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101691 · Cited by 47
Yaribash, S., Mohammadi, K., & Sani, M. A. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01544-2 · Cited by 46
Media hype: Patient and scientific perspectives on misleading medical news
Robledo, I., & Jankovic, J. J. (2017) · Movement Disorders · doi:10.1002/mds.26993 · Cited by 46
Genotype-driven therapeutic developments in Parkinson’s disease
Prasuhn, J., & Brüggemann, N. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00281-8 · Cited by 44
Alpha synuclein post translational modifications: potential targets for Parkinson’s disease therapy?
Brembati, V., Faustini, G., Longhena, F., & Bellucci, A. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1197853 · Cited by 44
Targeting dementias through cancer kinases inhibition
Fagiani, F., Lanni, C., Racchi, M., & Govoni, S. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12044 · Cited by 43
α‐Synuclein in Parkinson's Disease: From Bench to Bedside
Bellini, G., D’Antongiovanni, V., Palermo, G., Antonioli, L., Fornai, M., Ceravolo, R., Bernardini, N., Derkinderen, P., & Pellegrini, C. (2024) · Medicinal Research Reviews · doi:10.1002/med.22091 · Cited by 43
Brain penetrant kinase inhibitors: Learning from kinase neuroscience discovery
Shi, Y., & Mader, M. M. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.05.007 · Cited by 43
The Challenge of Disease-Modifying Therapies in Parkinson’s Disease: Role of CSF Biomarkers
Paoletti, F. P., Gaetani, L., & Parnetti, L. (2020) · Biomolecules · doi:10.3390/biom10020335 · Cited by 43
Baggett, D., Olson, A., & Parmar, M. S. (2024) · Brain Disorders · doi:10.1016/j.dscb.2024.100163 · Cited by 42
Protein Kinases and Parkinson’s Disease
Mehdi, S. J., Rosas-Hernández, H., Cuevas, E., Lantz, S. M., Barger, S. W., Sarkar, S., Paule, M. G., Ali, S. F., & Imam, S. Z. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091585 · Cited by 42
Miao, Y., & Meng, H. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01402-y · Cited by 42
Recent developments in the management of Huntington's disease
Devadiga, S., & Bharate, S. S. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105642 · Cited by 41
α-Synuclein oligomers and fibrils: partners in crime in synucleinopathies
Bigi, A., Cascella, R., & Cecchi, C. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.371345 · Cited by 40
New Frontiers in Parkinson's Disease: From Genetics to the Clinic
Shihabuddin, L. S., Brundin, P., Greenamyre, J. T., Stephenson, D. T., & Sardi, S. P. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.1666-18.2018 · Cited by 40
Nilotinib – Differentiating the Hope from the Hype
Wyse, R. K. H., Brundin, P., & Sherer, T. (2016) · Journal of Parkinson s Disease · doi:10.3233/jpd-160904 · Cited by 39
Top Altmetric Scores in the Parkinson’s Disease Literature
Araújo, R., Sorensen, A. A., Konkiel, S., & Bloem, B. R. (2016) · Journal of Parkinson s Disease · doi:10.3233/jpd-179000 · Cited by 39
Therapeutic Strategies in Huntington’s Disease: From Genetic Defect to Gene Therapy
Jurcău, A., & Jurcău, M. C. (2022) · Biomedicines · doi:10.3390/biomedicines10081895 · Cited by 41
Metadata
- Authors
- Pagan, F., Hebron, M., Valadez, E. H., Torres-Yaghi, Y., Huang, X., Mills, R. R., Wilmarth, B. M., Howard, H., Dunn, C., Carlson, A., Lawler, A., Rogers, S. L., Falconer, R. A., Ahn, J., Li, Z., & Moussa, C.
- Affiliations
- Department of Neurology, National Parkinson’s Foundation Center for Excellence, Translational Neurotherapeutics Program. Movement Disorders Program. MedStar Georgetown Hospital Washington, DC, USA
- Georgetown University Medical Center (US)
- MedStar Georgetown University Hospital (US)
- Corresponding author
- Moussa, Charbel
- Venue
- Journal of Parkinson’s Disease
- Publisher
- SAGE Publications
- Published
- 2016-06-03
- Volume
- 6
- Issue
- 3
- Pages
- 503-517
- ISSN
- 1877-7171 (ISSN-L)
- 1877-718X
- PMC
- PMC5008228
- OpenAlex
- W2462137239
- Cited by
- 265
- References
- 49
- Citations by year
- 2026: 14 · 2025: 12 · 2024: 20 · 2023: 23 · 2022: 37 · 2021: 34 · 2020: 32 · 2019: 38 · 2018: 30 · 2017: 17 · 2016: 7
- FWCI
- 23.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Parkinson s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Department of Health and Human Services (UL1RR031975)
- Georgia Clinical and Translational Science Alliance
- National Institutes of Health (UL1TR001409, UL1TR000101)
- National Center for Research Resources (UL1RR031975)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- nilotinib, Parkinson's disease, dementia with Lewy bodies, ABL tyrosine kinase inhibitors, cerebrospinal fluid pharmacokinetics, target engagement, homovanillic acid, cerebrospinal fluid biomarkers, drug safety and tolerability
- MeSH terms
- Dementia, Follow-Up Studies, Humans, Parkinson Disease, Pyrimidines, Outcome Assessment, Health Care, Lewy Body Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.